Innate Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Innate Pharma (IPHA).

Price Target Range — 12 Quarters

Analyst Consensus — 3 Analysts

2Buy

1Hold

Consensus RatingBuy# Analysts3Avg. Consensus PT$7Upside to Avg. PT+381.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 17, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$9
Aug 12, 2026	BTIG	Jeet Mukherjee	PT Raise	Buy	$8→$9
Aug 10, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$5→$7
Apr 7, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$5
Mar 12, 2026	BTIG	Jeet Mukherjee	Assumes	Buy	$8
Oct 29, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	Upgrade	Neutral→Buy	$5
Oct 29, 2025	BTIG	Justin Zelin	Maintained	Buy	$8
Sep 18, 2025	Leerink Partners	Daina Graybosch	Downgrade	Outperform→Market Perform	$10→$2
Sep 18, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	Downgrade	Buy→Neutral	—
Apr 24, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	PT Cut	Buy	$12→$11
Mar 28, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$12
Feb 6, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$12
Jan 17, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$12
Dec 9, 2024	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$12
Nov 15, 2024	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$12
Nov 12, 2024	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$12
Sep 13, 2024	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$12
Jun 12, 2024	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$12
May 15, 2024	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$12
Apr 11, 2024	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$12

Analyst Ratings News

PRO
BTIG Reiterates Buy on Innate Pharma, Maintains $9 Price Target

BTIG analyst Jeet Mukherjee reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $9 price target.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on Innate Pharma, Raises Price Target to $9

BTIG analyst Jeet Mukherjee maintains Innate Pharma (NASDAQ:IPHA) with a Buy and raises the price target from $8 to $9.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Innate Pharma, Raises Price Target to $7

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Innate Pharma (NASDAQ:IPHA) with a Buy and raises the price target from $5 to $7.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $5 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $5 price target.

Benzinga Newsdesk

PRO
BTIG Assumes Innate Pharma at Buy, Announces Price Target of $8

BTIG analyst Jeet Mukherjee assumes Innate Pharma (NASDAQ:IPHA) with a Buy rating and announces Price Target of $8.

Benzinga Newsdesk

This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday

Avi Kapoor

Innate Pharma SA

Innate Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
BTIG Reiterates Buy on Innate Pharma, Maintains $9 Price Target

PRO
BTIG Maintains Buy on Innate Pharma, Raises Price Target to $9

PRO
HC Wainwright & Co. Maintains Buy on Innate Pharma, Raises Price Target to $7

PRO
HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $5 Price Target

PRO
BTIG Assumes Innate Pharma at Buy, Announces Price Target of $8

This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday

People Also Watch

People Also Watch

Innate Pharma SA

Innate Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBTIG Reiterates Buy on Innate Pharma, Maintains $9 Price Target

PROBTIG Maintains Buy on Innate Pharma, Raises Price Target to $9

PROHC Wainwright & Co. Maintains Buy on Innate Pharma, Raises Price Target to $7

PROHC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $5 Price Target

PROBTIG Assumes Innate Pharma at Buy, Announces Price Target of $8

This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday

People Also Watch

People Also Watch

PRO
BTIG Reiterates Buy on Innate Pharma, Maintains $9 Price Target

PRO
BTIG Maintains Buy on Innate Pharma, Raises Price Target to $9

PRO
HC Wainwright & Co. Maintains Buy on Innate Pharma, Raises Price Target to $7

PRO
HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $5 Price Target

PRO
BTIG Assumes Innate Pharma at Buy, Announces Price Target of $8